Magmega Injection (Magnesium Sulfate Heptahydrate)

Adult administration

Convulsions due to hypomagnesemia: 1 to 2 g of magnesium sulfate should be administered intravenously (4.05 to 8.1 mmol). Eclamptic seizures: 4 to 5 g of this drug should be administered intravenously over 10 minutes (16.2 to 20.25 mmol). To prevent uterine rigidity: administer an initial dose of 4 g intravenously (16.2 mmol). Subsequently, 1 g may be administered. For electrolyte supplementation (hypomagnesemia): administer 1 g intramuscularly every 6 hours.

Child administration

The safety of this medication has not been tested.

This medication is a glass ampoule injectable product; therefore, glass fragments may contaminate when opening the container, requiring utmost care during use. Special caution is necessary when administering to children or the elderly. This drug should not be used in patients with poor kidney function, patients in a coma, patients with high blood magnesium levels, patients with cardiac conduction disorders, and patients with myasthenia gravis. Special caution should also be exercised when administering this drug to children with intestinal parasitic diseases or patients with heart conditions. Using this drug may result in gastrointestinal symptoms such as vomiting or dry mouth, and rarely, cardiac side effects such as conduction disorders or bradycardia may occur. Symptoms of autonomic nervous system involvement such as headache, heaviness, tremors, and tingling may also be reported. Overdose can lead to magnesium toxicity, with serious symptoms like a sense of heat, thirst, hypotension, central nervous system depression, cardiac suppression, and respiratory failure. In this case, calcium supplements should be administered intravenously for detoxification treatment. This drug may interact with other medications, so special caution is required, especially when used with central nervous system depressants, as their effects may be enhanced. Additionally, co-administration with iron supplements, certain antibiotics, or sodium fluoride may reduce the absorption of those drugs. This medication is used for the treatment of eclampsia during pregnancy but can cause decreased muscle tone or respiratory depression in the fetus, so fetal condition should be closely monitored. When administered during delivery, there is a risk of respiratory depression in the newborn; therefore, it is advisable not to use it within 2 hours post-delivery. Prolonged administration during pregnancy may affect fetal calcium and skeletal development, so it should be used cautiously. The safety of this drug during breastfeeding has not been established, and it is recommended not to use it unless absolutely necessary. The elderly may have decreased physiological function, so it is necessary to adjust the dosage and administer it slowly. In cases of overdose, serious symptoms such as arrhythmias, decreased consciousness, and respiratory depression may appear, and immediate cessation of administration and appropriate treatment should be obtained. When given intravenously, it should be injected slowly at concentrations less than 10% and should not be mixed with this drug and certain formulations to avoid precipitation. To prevent infection during administration, skin and instruments should be disinfected, and any remaining medication should not be reused after opening.

Serious side effects

Conduction disorders, bradycardia, respiratory failure due to magnesium toxicity

Mild side effects

• Vomiting
• dry mouth
• flushing
• peripheral vasodilation
• headache
• heaviness
• tremors
• tingling
• heat sensation at the injection site
• hypotension

This medication should be stored in a sealed container to prevent exposure to air, ideally at room temperature between 1 to 30 degrees Celsius. This storage preserves the medication's efficacy and prevents deterioration.

Appearance

Colorless liquid in a transparent plastic (polypropylene, polyethylene) container

Package unit

50 ampoules/box [(20 milliliters/plastic ampoule x 50)]